BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
Follow ONC
Alert me
BeOne Medicines Ltd. - Sponsored ADR (ONC) EV/FCF
As of 5 November 2026, BeOne Medicines Ltd. - Sponsored ADR (ONC) trades at a EV/FCF of 27.1×. Over the past ten years it has ranged from −149× (June 2025) to 159× (September 2025); the current reading is higher than 91% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 32.4× | — |
| FY2024 | −27.1× | — |
| FY2023 | −8.9× | — |
| FY2022 | −10.4× | — |
| FY2021 | −11.9× | — |
| FY2020 | −12.4× | — |
| FY2019 | −11.0× | — |
| FY2018 | −9.4× | — |
| FY2017 | −77.0× | — |
| FY2016 | −5.4× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 25.3× | 18.91% |
| Jun 2026 | 21.3× | (20.83%) |
| Mar 2026 | 26.9× | (17.00%) |
| Dec 2025 | 32.4× | (49.96%) |
| 40 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| INSM Insmed, Inc. compare | −37.2× |
| ROIV Roivant Sciences Ltd. compare | −28.1× |
| RVMD Revolution Medicines, Inc. compare | −25.0× |
| BNTX BioNTech SE Sponsored ADR compare | −9.6× |
| GMAB Genmab A/S Sponsored ADR compare | −5.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR | 27.1× |
| RPRX Royalty Pharma PLC compare | 29.5× |
| INCY Incyte Corporation compare | 29.7× |
| ARGX argenex SE compare | 38.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on ONC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement